Completed PHASE3 INTERVENTIONAL 2-arm NCT01065038

Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia (ANAHYDRET)

A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia

Sponsor: AOP Orphan Pharmaceuticals AG

Conditions Essential Thrombocythaemia

Interventions Anagrelide Hydroxyurea

Updated 6 times since 2017 Last updated: Oct 5, 2010 Started: Sep 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01065038, this PHASE3 trial focuses on Essential Thrombocythaemia and remains completed. Sponsored by AOP Orphan Pharmaceuticals AG, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AOP Orphan Pharmaceuticals AG

Data source: AOP Orphan Pharmaceuticals AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Brno, Czechia , Budapest, Hungary , Gdansk, Poland , Halle, Germany , Innsbruck, Austria , Katowice, Poland , Krakow, Poland , Ljubljana, Slovenia , Lodz, Poland and 13 more locations